



## IntegraGen lists on NYSE Alternext

Paris, 18 June 2010 - NYSE Euronext today announced the admission of IntegraGen, a pioneer in the development of molecular diagnostic tools, to NYSE Alternext.

IntegraGen is a major contender in clinical genomics, where it is developing a line of products and services for genetic diagnostic, the most dynamic segment of the in-vitro diagnostics market. The company offers clinical practitioners new diagnostic tools that favour the deployment of personalized treatment for complex illnesses in autism and oncology.

IntegraGen (ticker symbol: ALINT) was admitted to NYSE Alternext by direct listing of the 3,771,471 existing shares making up its capital. This followed the private placement with qualified investors of 800,149 new shares at a subscription price of €8.40 each, for a total €6.7 million.

Market capitalization of IntegraGen on the date of admission amounted to €1.7 million.

*“We are very proud to welcome IntegraGen to NYSE Alternext and to accompany it in a new phase in its development, comments Ronald Kent, Group Executive Vice President and Head of International Listings at NYSE Euronext. Going public will enable IntegraGen to extend its reach and strengthen a drive fully supported by NYSE Euronext to promote early diagnosis of complex conditions such as autism.”*

Bernard Courtieu, Chairman and Chief Executive of IntegraGen, adds: *“We are delighted with the success of our listing on NYSE Alternext, which has raised €6.7 million from leading qualified investors. IntegraGen is now in a position to significantly accelerate the development of our molecular diagnostic products and services and their use by clinician, in order to satisfy unmet needs in the fields of oncology and autism. This new stage in our company’s growth will position IntegraGen as a benchmark in innovation, constantly working to improve patient care.”*

NYSE Alternext today counts 141 listed companies from countries including Belgium, Canada, China, France, Italy, Luxembourg, the Netherlands, Spain, the UK and the US. Together they have raised over €2.3 billion, half of this through secondary issues, and their market capitalization totals €4.4 billion.

### Press contacts:

NYSE Euronext (Paris): +33 (0)1 49 27 11 33

### IntegraGen - Citigate Dewe Rogerson

Agnès Villeret - [agnes.villeret@citigate.fr](mailto:agnes.villeret@citigate.fr) : +33 (0)1 53 32 78 95

Lucie Larguier - [lucie.larguier@citigate.fr](mailto:lucie.larguier@citigate.fr): +33 (0)1 53 32 84 75



**About IntegraGen**

Located at the Evry Genopole site south of Paris, IntegraGen was founded in 2000 and is dedicated to research and identification of genetic biomarkers, and to the development and distribution of molecular diagnostic products and services. IntegraGen's strategy is to enable clinical practitioners to use new diagnostic tools, improving patient care, thanks to applications and intellectual property in two main fields: autism and oncology. IntegraGen's Business Genomic Services Unit also provides state-of-the-art genomic services and sequencing for scientific research.

**About NYSE Euronext**

NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets – the New York Stock Exchange, NYSE Euronext, NYSE Amex, NYSE Alternext and NYSE Arca – represent one-third of the world's equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index, and is the only exchange operator in the S&P 100 index and Fortune 500. For more information, please visit: [www.nyx.com](http://www.nyx.com)